Abstract 278P
Background
Burkitt Lymphoma (BL) is a rare and aggressive type of non-Hodgkin lymphoma (NHL), accounting for 0.8% of all B-cell lymphomas, with five-year survival ranging from 48% to 87%. Currently, intensive short-cycle and low-intensity multiagent immunochemotherapy regimens are used, however, it is not clear what health economic evidence exists for treatments in BL. Thereby, a systematic literature review (SLR) was conducted to understand the economic (costs and resource-use, economic evaluations) evidence base for patients with BL.
Methods
An SLR was conducted using Embase®, PubMed®, and EconLit from database inception through June 2019.
Results
A total of 758 abstracts and 132 full-texts were screened. We identified 2 economic evaluations and 7 studies reporting data for costs or resource-use covering four countries (Malawi, Nigeria, Uganda, Netherlands). The economic evidence varied in different regions due to unbalanced socio-economic development. The median length of hospital stay ranged from 13 days in Nigeria to 134 days in the Netherlands. The patients were also reluctant to healthcare and took 4-8 weeks from the onset of symptoms to present at the treatment centers in Nigeria. The total direct cost of treating BL was US$103.8 (Nigeria), US$350.14 (Uganda), and US$7342.17 (Netherlands) per patient. Dominant drivers for cost were the length of in-hospital stay and medication costs. Both the economic evaluations presented models for paediatric patients with no treatment as the comparator of choice and a continuous discount rate of 3%. Models were built from a governmental perspective with discounting and duration of treatment significantly impacting the sensitivity analysis. The cost per DALY averted was US$97 in Uganda and US$14,243 in Malawi, reflecting very cost-effective chemotherapeutic interventions.
Conclusions
This review highlights the limited literature on the economic dimensions of BL treatment, however, also demonstrates cost-effective interventions in resource-limited settings. There remains a need for future research and careful consideration of BL as an investment in health systems strengthening and improving the health outcomes.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
381P - XKR8 is a promising potential prognostic marker in glioblastoma multiforme patients
Presenter: Kristina Havrysh
Session: Poster display session
Resources:
Abstract
383P - Screening of prognostic molecular biomarker for resectable pancreatic cancer
Presenter: Yonggang Peng
Session: Poster display session
Resources:
Abstract
384P - Prevalence of abnormal microsatellite instability test among ovary and endometrial cancer patients
Presenter: Min Kyu Kim
Session: Poster display session
Resources:
Abstract
385P - Identifying CASP8 polymorphisms associated with breast cancer risk in an Iranian population
Presenter: Alireza Pasdar
Session: Poster display session
Resources:
Abstract
386P - Unusual folding of NaPi2b transporter extramembrane domain 4 during malignant transformation
Presenter: Leysan Minigulova
Session: Poster display session
Resources:
Abstract
387P - 5-years conditional disease free survival and overall survival for breast cancer patients in South Korea
Presenter: Jee hyun Ahn
Session: Poster display session
Resources:
Abstract
388P - To identify circulating tumour cells by machine learning approach
Presenter: Yuebin Liang
Session: Poster display session
Resources:
Abstract
389P - The establishment of patient-derived organoid models and drug response of resectable non-small cell lung cancer
Presenter: Jing-Hua Chen
Session: Poster display session
Resources:
Abstract
395P - Filipinos and lung cancer: An infodemiological assessment using Google trends from 2009 to 2019
Presenter: Lance Isidore Catedral
Session: Poster display session
Resources:
Abstract
396P - Determinants of visiting a referral hospital for cervical cancer screening at Uganda Cancer Institute
Presenter: Collins Mpamani
Session: Poster display session
Resources:
Abstract